These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38698025)

  • 41. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
    Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
    Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hereditary and acquired transthyretin-mediated amyloidosis].
    van der Bie MH; Louter L; Boots JMM; van Daele PLA; Klaassen SHC; Hazenberg BPC
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32186825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.
    Bay K; Gustafsson F; Maiborg M; Bagger-Bahnsen A; Strand AM; Pilgaard T; Poulsen SH
    ESC Heart Fail; 2022 Jun; 9(3):1524-1541. PubMed ID: 35343098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.
    Kharoubi M; Roche F; Bézard M; Hupin D; Silva S; Oghina S; Chalard C; Zaroui A; Galat A; Guendouz S; Canoui-Poitrine F; Hittinger L; Teiger E; Lefaucheur JP; Damy T
    ESC Heart Fail; 2021 Apr; 8(2):1656-1665. PubMed ID: 33354901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hereditary transthyretin amyloidosis: current treatment.
    Adams D; Slama M
    Curr Opin Neurol; 2020 Oct; 33(5):553-561. PubMed ID: 32796279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
    Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.
    Gimelli A; Aimo A; Vergaro G; Genovesi D; Santonato V; Kusch A; Emdin M; Marzullo P
    Amyloid; 2020 Dec; 27(4):237-243. PubMed ID: 32441155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
    Berends M; Nienhuis HLA; Adams D; Karam C; Luigetti M; Polydefkis M; Reilly MM; Sekijima Y; Hazenberg BPC
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
    ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.
    Cortese A; Vegezzi E; Lozza A; Alfonsi E; Montini A; Moglia A; Merlini G; Obici L
    J Neurol Neurosurg Psychiatry; 2017 May; 88(5):457-458. PubMed ID: 28188196
    [No Abstract]   [Full Text] [Related]  

  • 56. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis.
    Vera-Llonch M; Reddy SR; Chang E; Tarbox MH; Pollock M
    Orphanet J Rare Dis; 2021 Jan; 16(1):25. PubMed ID: 33430941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.